NEW YORK (GenomeWeb) – Rosetta Genomics today announced a deal to sell tests from Admera Health to oncologists and pathologists.
South Plainfield, NJ-based Admera is a molecular diagnostics spinoff of the clinical services unit of genomics contract research organization GeneWiz. As part of the deal, Rosetta will market Admera's tests, including PGxOne, which predicts how patients will respond to drugs based on their genetic profiles. Rosetta also will make available Admera's EGFR and KRAS clinical sequencing service.
"Combining Rosetta's Cancer Origin Test information on tumor type with Admera's powerful genomic tests provides physicians with clinically relevant and medically actionable information from which to define their treatment protocols, as opposed to using blind sequencing settings of anatomic uncertainty," Rosetta President and CEO Kenneth Berlin said in a statement. The deal potentially could accelerate revenue growth by expanding Rosetta's footprint in the metastatic cancer space while creating other cancer markets for the firm, he added.
"Through this partnership, we are able to engage Rosetta's extensive network of physicians and healthcare professionals to offer greater personalized testing options for patients," Admera CEO Steve Sun said.
Financial and other terms of the agreement were not disclosed.